tiprankstipranks
Trending News
More News >

Cutia Therapeutics’ Phase III Trial Results for CU-30101 Accepted for Presentation

Story Highlights
Cutia Therapeutics’ Phase III Trial Results for CU-30101 Accepted for Presentation

Don’t Miss TipRanks’ Half-Year Sale

Cutia Therapeutics ( (HK:2487) ) has shared an update.

Cutia Therapeutics announced that its Phase III clinical trial results for CU-30101, a localized topical lidocaine and tetracaine cream, were accepted for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology. The trial demonstrated that CU-30101 is as effective as the reference product, Pliaglis®, in providing analgesia with a favorable safety profile, leading to the submission of a marketing authorization application to the National Medical Products Administration.

More about Cutia Therapeutics

Cutia Therapeutics is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry with a focus on dermatology. The company specializes in developing topical anesthesia products, such as the CU-30101 cream, which is aimed at providing localized analgesia for dermatologic procedures.

Average Trading Volume: 1,602,118

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$2.95B

See more insights into 2487 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1